Parallel Advisors
NAGE icon

Parallel Advisors’s Niagen Bioscience NAGE Stock Holding History

Parallel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$975 Buy
334
+284
+568% +$906 ﹤0.01% 3791
2026
Q2 		$160 Buy
+50
New +$203 ﹤0.01% 3860
2021
Q3 		– Sell
-100
Closed -$1K – 3303
2021
Q2 		$1K Buy
+100
New +$872 ﹤0.01% 2863

Other funds holding NAGE

SteelPeak Wealth
SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $211M AUM 58.81% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Chicago Partners Investment Group
Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return
Midwest Professional Planners Ltd (MPPL)
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $506M AUM 37.62% 1-Year Est. Return

Parallel Advisors's NAGE Position: Q3 2026 in Review

Parallel Advisors increased its Niagen Bioscience (NAGE) stake by 568% in Q3 2026, buying an estimated $906 and bringing the position to 334 shares worth $975. The position accounts for ﹤0.01% of the portfolio, ranked #3791.

Parallel Advisors first reported a position in NAGE in Q2 2021 and has held it in 3 quarters since. The position peaked at $1K in Q2 2021. 28 funds tracked by Wall St. Rank hold NAGE as of Q3 2026.

  • Parallel Advisors held 334 shares of Niagen Bioscience worth $975 as of Q3 2026.
  • Parallel Advisors bought 284 Niagen Bioscience shares in Q3 2026, an estimated $906.
  • Niagen Bioscience made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3791 holding.
  • Parallel Advisors first reported a position in Niagen Bioscience in Q2 2021 and has held it in 3 quarters since.
  • Parallel Advisors's Niagen Bioscience position peaked at $1K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.